JAK Inhibitor News and Research

RSS

Unraveling nuanced roles of JAK inhibitors in inflammation

Researchers at the Icahn School of Medicine at Mount Sinai have gained a deeper understanding of the nuanced roles of JAK inhibitors, or modulators, in inflammation across various cell types and tissues.

21 Dec 2023

Two new practice parameters offer recommendations for treating anaphylaxis and atopic dermatitis

Two new practice parameters from the Joint Task Force for Practice Parameters (JTFPP) offer evidence-based recommendations for the diagnosis and management of anaphylaxis and atopic dermatitis (AD) in pediatric and adult patients.

18 Dec 2023

New drug combination doubles effectiveness in shrinking enlarged spleens in myelofibrosis patients

Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens – a major indicator of clinical improvement – compared with standard-of-care ruxolitinib monotherapy for adult patients with intermediate or high-risk myelofibrosis, a rare bone marrow cancer, according to results of the Phase III TRANSFORM-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center.

11 Dec 2023

JAK inhibitors offer effective and convenient treatment option for arthritis patients

According to a new paper in Rheumatology, published by Oxford University Press, JAK inhibitors, which doctors have used to treat patients with arthritis despite concerns about the effectiveness of such drugs, actually do work quite well.

1 Nov 2023

Lack of direct comparisons prevents assessment of upadacitinib's benefit in Crohn's disease

Like several immunosuppressive biologics, the JAK inhibitor upadacitinib is also approved for the treatment of Crohn's disease. Commissioned by the Federal Joint Committee (G-BA), the Institute for Quality and Efficiency in Health Care (IQWiG) has now investigated in an early benefit assessment whether the drug offers an added benefit versus the appropriate comparator therapy to patients with moderate to severe active Crohn's disease who have had an inadequate response, lost response or are intolerant to conventional therapy or a biologic agent.

25 Oct 2023

Study reveals immune dysregulation in Down syndrome and potential therapeutic strategy

People with Down syndrome, the condition caused by an extra copy of chromosome 21, or trisomy 21, display chronic dysregulation of their immune system, which can contribute to high rates of autoimmune conditions and severe complications from respiratory infections.

17 Jul 2023

Patients with myelofibrosis show improvement in disease-related symptoms when treated with momelotinib

Patients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, when treated with the targeted therapy momelotinib, according to results from the international Phase III MOMENTUM trial led by researchers at The University of Texas MD Anderson Cancer Center.

29 Jan 2023

CHLA launches first clinical trial for Down syndrome regression disorder with $5.3 million NIH grant

Children's Hospital Los Angeles has launched the first clinical trial for Down syndrome regression disorder (DSRD), a rare and debilitating condition that affects adolescents and young adults with Down syndrome.

23 Jan 2023

Study reviews mechanistic data on new methods of allergy prevention and treatment

In a recent article published in Science Translational Medicine, researchers reviewed the cause and the underlying pathophysiology of allergic diseases.

23 Jan 2023

Does skin inflammation exacerbate COVID-19?

In a new study, researchers discussed inflammation during infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

18 Oct 2022

Antibody drugs are not recommended for patients with covid-19, say WHO experts

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with covid-19, says a WHO Guideline Development Group of international experts in The BMJ today.

16 Sep 2022

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

With this approval, RINVOQ® is the first and only Janus Kinase inhibitor approved to treat patients across the spectrum of axial spondyloarthritis (nr-axSpA and ankylosing spondylitis) in the EU.

From AbbVie 29 Jul 2022

Oral pill taken once a day improves outcomes of patients with myelofibrosis

Momelotinib, an oral pill taken once a day, significantly improved outcomes of patients treated for myelofibrosis (MF), a rare but fatal bone marrow cancer, researchers reported June 7.

7 Jun 2022

Cycling JAK inhibitors can be effective for treating people with difficult-to-treat rheumatoid arthritis

New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that people with difficult-to-treat rheumatoid arthritis who do not have success with one Janus kinase inhibitor (JAK inhibitor) can achieve success either cycling to other JAKi medications or switching to a biologic drug.

2 Nov 2021

Study shows impaired SARS-CoV-2 mRNA vaccine antibody response in individuals with chronic conditions

A recent study in Colorado used real-world data to evaluate if individuals with chronic conditions have reduced antibody response to COVID-19 mRNA vaccines. The study investigated whether some medical conditions may impact antibody response to the mRNA vaccines.

9 Aug 2021

Autoimmune condition biomarkers promote SARS-CoV-2 viral entry, study finds

Researchers have reported that the autoimmune PTPN2 risk variant rs1893217 promotes the expression of the SARS-CoV-2 receptor, ACE2, and thus promotes cellular entry, which is mediated by SARS-CoV-2 spike S protein.

16 Dec 2020

Novel super-activating macrophage receptor could explain hyper-inflammation in severe COVID-19

Immunity is a curious thing. While essential in protecting the body against invading pathogens and foreign antigens, it can also turn against the body and trigger destructive immunological processes. A new study published on the preprint server bioRxiv* in November 2020 reports on the role played by hyperactive macrophages in a range of acute and chronic hyper-inflammatory conditions.

10 Nov 2020

Study shows tofacitinib drug can repair permeability defects in the intestine

A team of researchers led by biomedical scientist Declan F. McCole at the University of California, Riverside, has found that the drug tofacitinib, also called Xeljanz and approved by the FDA to treat rheumatoid arthritis and ulcerative colitis, can repair permeability defects in the intestine.

30 Sep 2020

Researchers discover treatment for severe auto inflammatory syndrome

Researchers from the Icahn School of Medicine used a novel genetic sequencing technology to identify the genetic cause of--and a treatment for--a previously unknown severe auto inflam-matory syndrome affecting an 18-year-old girl since infancy.

4 Aug 2020

Insilico Medicine, Arctoris announce technology partnership to discover new COVID-19 drugs

Insilico Medicine, a biotechnology company developing an end-to-end drug discovery pipeline utilizing next-generation artificial intelligence, today announced a technology partnership with Arctoris, the world's first fully automated drug discovery platform, offering remotely accessible, pre-optimized and fully validated R&D processes for its partners and clients globally.

9 Jul 2020